TLDR
- Aethlon Medical stock surged over 471% in premarket trading on September 17, 2026, after announcing a merger with North Immunology
- The all-stock deal will create a new Nasdaq-listed company called North Immunology, Inc., trading under the ticker NRTX
- North Immunology shareholders and PIPE investors will own around 95% of the combined company; Aethlon holders get roughly 4.75%
- A $180 million private placement, backed by major healthcare investors including Bain Capital Life Sciences and Janus Henderson, will fund operations into late 2028
- Lead drug candidate NOR-101, a bispecific antibody for atopic dermatitis, is set to enter Phase 1a trials in early 2027
Aethlon Medical (AEMD) stock exploded over 471% in premarket trading Thursday after the company announced a definitive all-stock merger agreement with privately held biotech North Immunology.
The deal, announced September 17, 2026, will see the two companies combine through wholly owned subsidiaries Nighthawk Merger Sub Corp. and Nighthawk Second Merger Sub, LLC.
The resulting company will be named North Immunology, Inc. and list on the Nasdaq Capital Market under the new ticker symbol NRTX.
Under the terms of the agreement, North Immunology shareholders and new PIPE investors will own approximately 95.25% of the combined company.
Aethlon’s existing shareholders will be left with roughly 4.75% of the new entity, along with contingent value rights tied to the monetization of Aethlon’s legacy Hemopurifier business.
The merger comes alongside an oversubscribed $180 million private placement, a sign that institutional appetite for the deal was strong.
That financing was led by a group of healthcare-focused investors including Bain Capital Life Sciences, Janus Henderson Investors, Deep Track Capital, Longitude Capital, Soleus Capital, Invus, Sirenia Capital Management LP, Farallon Capital Management, Adage Capital Partners LP, and TCGX.
Included in the $180 million is the conversion of approximately $34 million in North Immunology’s outstanding convertible promissory notes, plus any accrued interest, premiums, and fees.
The proceeds are expected to fully fund the combined company’s operations into the second half of 2028.
What North Immunology Is Working On
North Immunology is focused on bispecific antibodies that target inflammatory pathways in immune-mediated diseases.
Its lead candidate, NOR-101, is a half-life extended IL-13 x IL-18 bispecific antibody being developed primarily for atopic dermatitis.
Clinical Timeline for NOR-101
The Phase 1a study of NOR-101 is expected to kick off in the first quarter of 2027, with interim pharmacokinetic and safety data expected by mid-2027.
The company plans to initiate both Phase 1b and Phase 2b studies for atopic dermatitis in 2027.
Topline data from both of those studies is expected in 2028.
The merger itself is expected to close in the first quarter of 2027, pending shareholder, regulatory, and listing approvals.
North Immunology’s existing management team and board will lead the combined company after the deal closes.
The most recent analyst rating on AEMD stock is a Hold, with a price target of $1.50, according to TipRanks data.
Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions — all in one powerful platform.
Sign up today and get 50% OFF full access to our premium stock picks.
Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount.
Be the first to comment